{
    "nctId": "NCT06199895",
    "briefTitle": "Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer",
    "officialTitle": "Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxanes-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Stomach Cancer, Esophageal Carcinoma, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 25,
    "primaryOutcomeMeasure": "Objective Response Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1.Male or female 18 years and older; 2.Patients with advanced pancreatic adenocarcinoma, cholangiocarcinoma, lung cancer, gastric cancer, esophageal carcinoma, or breast cancer diagnosed by histological or cytological pathology; must have an evaluable lesion; 3.Previous treatment regimen includes Taxanes and is resistant to Taxanes (including patients with initial failure to remit or progression after remission) or previous use of Taxanes for at least 2 cycles without tumour shrinkage and the patient is not satisfied with current stable efficacy and is willing to be enrolled in this study; 4.ECOG (Eastern Cooperative Oncology Group) score \u2264 2 points; 5.expected survival of at least 3 months; 6.Blood routine examination meets the following criteria:\n\n  1. WBC\u22653.0\u00d7109 /L\uff0cANC\u22651.5\u00d7109 /L;\n  2. PLT\u2265100\u00d7109 /L\uff1b\n  3. Hb\u226580g/L\uff1b 7.Blood biochemical examination must meet the following criteria:\n\n  <!-- -->\n\n  1. Total bilirubin \u22641.5 times the upper limit of normal (ULN)\uff1b\n  2. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) \u22642.5 times ULN (ALT, AST, or ALP\u2264 5\u00d7ULN for subjects with liver metastases, and ALP\u226410\u00d7ULN for subjects with bone metastases);\n  3. Creatinine clearance (calculated using Cockcroft-Gault formula) \u226550 ml/min\uff1b 8.Functions of major organs such as heart, lung, liver and kidney are basically normal\uff1b 9.Subjects have good compliance and voluntarily comply with the clinical trial protocol during the study, followed up by the investigators\uff1b 10.All women of childbearing age, men of childbearing potential, or their spouses who have no plans to have children or donate sperm during the entire trial period and up to 6 months after the last dose of medication, or who voluntarily used effective contraception; Women of childbearing age who have a negative blood/urine pregnancy test within 7 days prior to enrollment\uff1b 11.Subjects had fully understood the study and voluntarily signed the informed consent form .\n\nExclusion Criteria:\n\n* 1.Subjects with an allergic history to experimental drugs or any excipients\uff1b 2.Subjects with acute or chronic infections that have not been eliminated, or subjects with other serious diseases at the same time; 3.Subjects with active hepatitis and uncontrolled by antiviral therapy, or liver metastasis is more than 3/4 of the whole liver\uff1b 4.Subjects with third-space effusions (e.g., moderate-to-massive pleural effusion, moderate-to-massive pericardial effusion, ascites) that cannot be controlled by drainage or other means; 5.Subjects with mental illness or disorder, poor compliance, or inability to cooperate, or describe treatment responses\uff1b 6.Subjects who cannot tolerate chemotherapy due to severe organic disease or major organ failure, such as decompensated heart and lung failure\uff1b 7.Subjects with bleeding disorders\uff1b 8.Subjects with organ transplant; 9.Subjects with bad drug addicts, long-term alcoholics, infectious diseases such as AIDS\uff1b 10.Subjects who still have grade \u22652 toxicity from previous antineoplastic therapy (except alopecia and grade \u22642 neurotoxicity caused by platinum) at enrollment; 11.Subjects are considered not able to complete the trial or otherwise unfit to participate in the study by the investigators.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}